- First quarter net income for Kyowa Kirin was 14.63 billion yen, which marks a 15% increase y/y, however it was still below the estimate of 15.1 billion yen.
- Net sales amounted to 105.57 billion yen, a 13% increase y/y, but again short of the predicted 107.56 billion yen.
- R&D expenses drastically increased by 40% y/y to the sum of 23.32 billion yen.
- Core operating profit saw a moderate increase of 2.5% from the previous year, totaling 17.40 billion yen.
- Despite these figures, the year forecast remains optimistic. The expected net income is still 63.00 billion yen, although slightly less than the predicted 66.01 billion yen.
- The net sales estimate stands at 473.00 billion yen, a tad higher than the 472.14 billion yen projected earlier.
- Dividend forecasts remain consistent at 58.00 yen, only slightly off the estimated 58.40 yen.
- The company currently has 5 buys, 7 holds, and 0 sells.
- All these comparisons are based on the values reported by the company in its original disclosures.
Kyowa Kirin Co Ltd on Smartkarma
Analyst coverage of Kyowa Kirin Co Ltd on Smartkarma has been positive, with research reports highlighting recent portfolio strengthening initiatives aimed at accelerating long-term growth. Tina Banerjee‘s report titled “Kyowa Kirin (4151 JP): Recent Portfolio Strengthening Initiatives to Accelerate Long-Term Growth” discusses the company’s partnership with Bridgebio for infigratinib in Japan and enrollment of the first patient in a Phase 2 trial for tivozanib eye drops for DME. While the top-selling drug Crysvita is performing well, higher R&D expenses are expected to impact near-term profits, as outlined in the report.
A look at Kyowa Kirin Co Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Kyowa Kirin Co Ltd, a pharmaceutical company, has been assessed using the Smartkarma Smart Scores. The company received a strong score of 5 in Resilience, indicating its ability to withstand challenges. With a Growth score of 4 and Momentum score of 4, Kyowa Kirin shows promising signs of expansion and market performance. While Value and Dividend scores are at a steady 3, suggesting a balanced financial standing. Overall, Kyowa Kirin Co Ltd‘s outlook appears positive for the long-term, especially with its solid Resilience rating.
Based on the provided Smartkarma Smart Scores, Kyowa Kirin Co Ltd is positioned well for future growth and stability. Its focus on pharmaceuticals, including innovative products developed using genetic technology, demonstrates a commitment to advancement in the industry. With a balanced performance across various factors, Kyowa Kirin has the potential to continue its upward trajectory and establish itself as a key player in the pharmaceutical market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
